VLA2001

BIOLOGICAL5 trials

Sponsors

Valneva Austria GmbH

Conditions

SARS-CoV-2 InfectionSARS-CoV-2 Virus Infection

Phase 1

Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy Subjects

CompletedNCT04671017

Valneva Austria GmbHSARS-CoV-2 Virus Infection

Start: 2020-12-16End: 2022-04-06Updated: 2022-04-22

Phase 2

COVID-19 Paediatric VLA2001-321 Study

WithdrawnNCT05298644

Valneva Austria GmbHSARS-CoV-2 Infection

Start: 2022-10-01End: 2025-08-30Updated: 2022-11-08

VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection

CompletedNCT05364242

Valneva Austria GmbHSARS-CoV-2 Infection

Start: 2022-05-09End: 2023-05-22Updated: 2023-06-07

Phase 3

COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222

CompletedNCT04864561

Valneva Austria GmbHSARS-CoV-2 Virus Infection

Start: 2021-04-26End: 2023-03-13Updated: 2023-03-20

Safety and Immunogenicity of VLA2001 Adults Aged ≥56 Years

CompletedNCT04956224

Valneva Austria GmbHSARS-CoV-2 Virus Infection

Start: 2021-08-09End: 2022-11-18Updated: 2023-09-01

Related Papers

Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.

2023-07-038 citations

EFFECTS OF HOMOLOGOUS AND HETEROLOGOUS BOOSTER VACCINATIONS OF THE INACTIVATED DUAL-ADJUVANTED VACCINE VLA2001 AGAINST COVID-19 INCLUDING VARIANTS OF CONCERN: A PHASE 3 RANDOMIZED CLINICAL TRIAL

International Journal of Infectious Diseases2023-05-011 citations

Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial

The Lancet Infectious Diseases2022-09-0547 citations

Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults.

2022-06-1619 citations